Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival
暂无分享,去创建一个
Constanze Zeller | Nadeem Siddiqui | Euan Stronach | Robert Brown | J. Graham | J. Flanagan | E. Stronach | N. Siddiqui | J. Paul | J. Teodoridis | Robert Brown | James M Flanagan | D. Millan | C. Zeller | W. Dai | Wei Dai | Jim Paul | Jens M Teodoridis | Janet Graham | Jenny Hersey | David W Millan | J. Hersey
[1] P. Lochhead,et al. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. , 2002, Endocrinology.
[2] David Haussler,et al. The UCSC genome browser database: update 2007 , 2006, Nucleic Acids Res..
[3] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[4] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Boyer,et al. WNT signaling in ovarian follicle biology and tumorigenesis , 2010, Trends in Endocrinology & Metabolism.
[6] Q. Tao,et al. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. , 2009, Epigenetics.
[7] M. Sugita,et al. Mutations of the β- and γ-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas , 2001, British Journal of Cancer.
[8] F. Demirkıran,et al. Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. , 2010, Journal of gynecologic oncology.
[9] E. Trimble,et al. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Bast,et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.
[11] G. Strathdee,et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.
[12] Russ B. Altman,et al. Missing value estimation methods for DNA microarrays , 2001, Bioinform..
[13] E. Raleigh,et al. McrBC: a multisubunit GTP-dependent restriction endonuclease. , 1992, Journal of molecular biology.
[14] Richard G. Moore,et al. Current state of biomarker development for clinical application in epithelial ovarian cancer. , 2010, Gynecologic oncology.
[15] A. Makrigiannakis,et al. Endometrial Pinopodes and Uterine Receptivity , 2003, Annals of the New York Academy of Sciences.
[16] Mitsuaki Suzuki,et al. Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.
[17] Trevor Hastie,et al. Imputing Missing Data for Gene Expression Arrays , 2001 .
[18] M. Narro,et al. Epigenomic Changes during Leukemia Cell Differentiation: Analysis of Histone Acetylation and Cytosine Methylation Using CpG Island Microarrays , 2004, Journal of Pharmacology and Experimental Therapeutics.
[19] Y. Taketani,et al. Methylation‐associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers , 2004, Cancer science.
[20] M. Brady,et al. Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience , 2010, Cancer.
[21] Stewart Fj,et al. Dependence of McrBC cleavage on distance between recognition elements. , 1998 .
[22] Gong Yang,et al. Ovarian cancer: pathology, biology, and disease models. , 2009, Frontiers in bioscience.
[23] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[24] A. Berchuck,et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[26] E. Berns,et al. MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.
[27] E. Raleigh,et al. Dependence of McrBC cleavage on distance between recognition elements. , 1998, Biological chemistry.
[28] Thomas Lengauer,et al. CpG Island Mapping by Epigenome Prediction , 2007, PLoS Comput. Biol..
[29] Hsien-yu Wang,et al. Differential mediation of the Wnt canonical pathway by mammalian Dishevelleds-1, -2, and -3. , 2008, Cellular signalling.
[30] A. Berns,et al. Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways , 2010, Oncogene.
[31] P. Bolufer,et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia , 2009, Leukemia.
[32] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[33] Robert Brown,et al. The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.
[34] N. Park,et al. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. , 2009, Gynecologic oncology.
[35] Wei Jiang,et al. Wnt/beta-catenin signaling pathway as a novel cancer drug target. , 2004, Current cancer drug targets.
[36] Randall T Moon,et al. Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways , 1999, Oncogene.
[37] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[38] T. Alonzo,et al. Molecular Cancer BioMed Central Review , 2007 .
[39] E. E. Gresch. Genetic Alterations During Colorectal-Tumor Development , 1989 .
[40] A. Silver,et al. The opposing roles of Wnt-5a in cancer , 2009, British Journal of Cancer.
[41] Robert S Illingworth,et al. CpG islands – ‘A rough guide’ , 2009, FEBS letters.
[42] Sandya Liyanarachchi,et al. Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.
[43] M. McKay,et al. Cancer of the ovary. , 1994, The New England journal of medicine.
[44] Kathleen R. Cho,et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.
[45] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[46] Mary Goldman,et al. The UCSC Genome Browser database: update 2011 , 2010, Nucleic Acids Res..
[47] Maria P. Pavlou,et al. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer , 2010, Nature Reviews Cancer.
[48] H. Su,et al. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway , 2010, International journal of cancer.
[49] B. Monk,et al. Wnt signaling in ovarian tumorigenesis , 2007, International Journal of Gynecologic Cancer.
[50] L. Frati,et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.
[51] Hideki Yamamoto,et al. Tumor formation due to abnormalities in the β‐catenin‐independent pathway of Wnt signaling , 2008, Cancer Science.
[52] Daniel E. Deatherage,et al. Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer , 2010, Laboratory Investigation.
[53] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[54] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[55] G. Klarmann,et al. Epigenetic gene silencing in the Wnt pathway in breast cancer , 2008, Epigenetics.
[56] Bert Vogelstein,et al. Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .
[57] P. Laird. Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.
[58] H. Hollema,et al. Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.
[59] M. Frommer,et al. CpG islands in vertebrate genomes. , 1987, Journal of molecular biology.
[60] Gerald L. Arthur,et al. Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia. , 2010, Epigenomics.
[61] Jun Yu,et al. Promoter methylation of the Wnt/β‐catenin signaling antagonist Dkk‐3 is associated with poor survival in gastric cancer , 2008, Cancer.
[62] Yingqun Wang,et al. Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy , 2009, Molecular Cancer Therapeutics.
[63] Qin He,et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. , 2008, Gynecologic oncology.
[64] Pearlly Yan,et al. Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands , 2008, BMC Bioinformatics.
[65] Nicola Ragni,et al. HER2/neu Oncoprotein Overexpression in Epithelial Ovarian Cancer: Evaluation of its Prevalence and Prognostic Significance , 2005, Oncology.
[66] J.,et al. The New England Journal of Medicine , 2012 .
[67] A. Sparks,et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.
[68] Meng Li,et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer , 2009, BMC Medical Genomics.
[69] Yun Deng,et al. Epigenetic silencing of WIF-1 in hepatocellular carcinomas , 2010, Journal of Cancer Research and Clinical Oncology.
[70] G. Kristiansen,et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis , 2006, Oncogene.
[71] P. Laird,et al. Sensitive Detection of DNA Methylation , 2003, Annals of the New York Academy of Sciences.
[72] Corneel Coens,et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial , 2010, The Lancet.
[73] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[74] S. Cannistra,et al. Gene-expression profiling in epithelial ovarian cancer , 2008, Nature Clinical Practice Oncology.